Co-Diagnostics, Inc.: management transactions · United States · SEC (Form 4)

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. (ticker: CODX) is a U.S.-based molecular diagnostics company listed on NASDAQ in the United States (United States). The company develops, manufactures and commercializes PCR-based diagnostic reagents and test solutions, with a core focus on infectious-disease detection and broader molecular-testing applications for human health, animal health and laboratory use cases. Its key differentiator is the proprietary Co-Primers™ technology, which the company presents as the foundation of its molecular test-design platform and as a tool to improve specificity in multiplex assays while reducing primer-dimer propagation. Co-Diagnostics was founded in 2013 and is headquartered in Salt Lake City, Utah. The company’s history includes a significant acceleration during the COVID-19 period, when it brought several diagnostic products to market and built brand recognition around its molecular-testing capabilities. While COVID-related demand helped establish the platform, management now emphasizes a broader product roadmap beyond the pandemic, leveraging the same proprietary technology to design tests for additional pathogens and future diagnostic targets. The group also highlights an international commercial footprint, stating that its products have been deployed through distributors and laboratories in more than 50 countries, which gives it a meaningful global reach relative to its size. From a competitive standpoint, Co-Diagnostics remains a niche player in a market dominated by much larger and better-capitalized diagnostics groups. Its investment case rests on intellectual property, assay-design expertise and the potential scalability of its test-development platform. The company is also positioning the Co-Dx PCR platform as a more decentralized testing solution, which could expand its addressable market if regulatory approvals and commercialization efforts progress as planned. However, the business remains exposed to the usual diagnostics-sector constraints: regulatory timing, commercialization execution, dependence on external financing, and strong competition from established global peers. Recent corporate developments have included quarterly and annual earnings releases, a registered direct offering in 2025, and continued commentary on pipeline progress and international expansion. Management has also flagged new product development and geographic initiatives in the Middle East and Europe, indicating that Co-Diagnostics is trying to broaden its commercial base beyond legacy COVID-related demand. For investors in French-speaking markets, CODX should be viewed as a technology-driven healthcare stock with speculative characteristics, supported by patented molecular diagnostics IP but still working toward consistent scale and profitability.